RP.V - RepliCel Life Sciences Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.3200
+0.0100 (+3.23%)
As of 10:39AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.3100
Open0.3400
Bid0.31 x 0
Ask0.32 x 0
Day's Range0.3100 - 0.3400
52 Week Range0.3000 - 0.6800
Volume8,720
Avg. Volume14,754
Market Cap9.432M
Beta (3Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateNov 27, 2015 - Nov 30, 2015
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.64
  • RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
    CNW Group3 months ago

    RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs

    VANCOUVER, Nov. 06, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF - News) (TSXV:RP.V - News) (FRA:P6P2.F - News) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announces the appointment of European Clinical and Regulatory Affairs expert, Dr. Petra Goessens-Rueck, as Head of Clinical and Regulatory Affairs. Dr. Petra Goessens-Rueck has been a valuable consultant to RepliCel since its inception assisting with research, development, clinical and regulatory strategy in addition to managing regulatory submissions and most aspects of the Company's clinical trials.

  • Baystreet4 months ago

    Stocks in play: RepliCel Life Sciences Inc.

    Has signed a collaborative research project agreement with the University of Victoria, B.C. The project ...

  • RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada
    CNW Group4 months ago

    RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada

    VANCOUVER and VICTORIA, BC, Oct. 18, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF - News) (TSXV:RP.V - News) (FRA:P6P2.F - News) ("RepliCel" or the "Company") is pleased to announce it has signed a collaborative research project agreement with the University of Victoria ("UVic") in Victoria, B.C., Canada. The project will be co-funded through a grant from the National Science and Engineering Research Council of Canada ("NSERC") under the NSERC Collaborative Research and Development ("CRD") program.

  • RepliCel Life Sciences Appoints New Chief Financial Officer
    CNW Group4 months ago

    RepliCel Life Sciences Appoints New Chief Financial Officer

    VANCOUVER, Oct. 17, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF - News) (TSXV:RP.V - News) (FRA:P6P2.F - News) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announces that its board of directors has appointed Simon Ma as the Chief Financial Officer of the Company.  Mr. Ma is the current Director of Finance and succeeds Tom Kordyback who has resigned as the Chief Financial Officer to enjoy his full-time retirement from professional service. Mr. Ma is a Chartered Professional Accountant and has extensive experience with private and public companies.

  • RepliCel CEO Provides Updated Outlook
    CNW Group4 months ago

    RepliCel CEO Provides Updated Outlook

    VANCOUVER, Oct. 15, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF - News) (TSXV:RP.V - News) (FRA:P6P2.F - News) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide an update to shareholders from its President and CEO, Mr. R. Lee Buckler. Now that we have closed our deal with YOFOTO, I am very pleased to provide this updated outlook. In January, I outlined our progress over the past 24 months and included our goals for 2018 which, I said, would be focused on "...leveraging partnerships to drive the Company towards maturation." Last week, we announced we had closed an investment with YOFOTO (China) Health Industry Co. Ltd ("YOFOTO"), which is now a significant shareholder and business partner.

  • RepliCel Life Sciences Completes Financing with YOFOTO (China) Health
    CNW Group4 months ago

    RepliCel Life Sciences Completes Financing with YOFOTO (China) Health

    VANCOUVER and NINGBO, China, Oct, 11, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF - News) (TSXV:RP.V - News) (FRA:P6P2.F - News) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced today it has completed the anticipated strategic investment (the "Transaction") with YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO").

  • RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment
    CNW Group5 months ago

    RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment

    VANCOUVER and NINGBO, China, Sept. 24, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF - News) (TSXV:RP.V - News) (FRA:P6P2.F - News) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has received, from the TSX Venture Exchange, the conditional approval required to complete the investment which is part of a previously announced collaboration agreement (the "Transaction") focused on commercialization of select RepliCel products in Greater China.

  • RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China
    CNW Group7 months ago

    RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China

    VANCOUVER and NINGBO, Zhejiang Province, China, July 11, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF - News) (TSXV:RP.V - News) (FRA:P6P2.F - News) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it has now signed definitive agreements with YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO") sealing its partnership to commercialize three of RepliCel's programs in Greater China.

  • RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO
    CNW Group10 months ago

    RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO

    VANCOUVER and NINGBO, Zhejiang Province, China, May 2, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF - News) (TSXV:RP.V - News) (FRA:P6P2.F - News) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce it now has a new Binding Term Sheet (the "Term Sheet") with YOFOTO (China) Health Industry Co. Ltd. ("YOFOTO") which both parties believe represents a stronger deal for both sides and positions them to finalize the transaction in the very near-term.